CannaPharmaRx delays third-quarter report as information gathering lags
CPMD•
CPMD•CannaPharmaRx delayed its report for the quarter ended September 30, 2026, and expects to file no later than the fifth calendar day after its due date. Revenue fell to $137,705 from $656,606, while net income was $645,416, primarily reflecting a $1.73 million noncash gain.
CannaPharmaRx said delays obtaining and compiling required information postponed its quarterly report for the period ended September 30, 2026. The company expects to file no later than the fifth calendar day following the prescribed due date. Revenue fell to $137,705 from $656,606 a year earlier, primarily because of lower cannabis sales volumes. Net income was $645,416, versus a year-earlier net loss of $1.48 million; the profit primarily reflected a $1.73 million noncash gain from the change in fair value of the derivative conversion feature.